South Korea
· Delayed Price · Currency is KRW Medy-Tox Statistics
Total Valuation
Medy-Tox has a market cap or net worth of KRW 704.68 billion. The enterprise value is 735.03 billion.
| Market Cap | 704.68B |
| Enterprise Value | 735.03B |
Important Dates
The next estimated earnings date is Friday, May 15, 2026.
| Earnings Date | May 15, 2026 |
| Ex-Dividend Date | Sep 29, 2025 |
Share Statistics
Medy-Tox has 6.56 million shares outstanding. The number of shares has decreased by -2.03% in one year.
| Current Share Class | 6.56M |
| Shares Outstanding | 6.56M |
| Shares Change (YoY) | -2.03% |
| Shares Change (QoQ) | -14.63% |
| Owned by Insiders (%) | 20.79% |
| Owned by Institutions (%) | 11.27% |
| Float | 5.12M |
Valuation Ratios
The trailing PE ratio is 45.34 and the forward PE ratio is 27.99.
| PE Ratio | 45.34 |
| Forward PE | 27.99 |
| PS Ratio | 2.85 |
| PB Ratio | 1.55 |
| P/TBV Ratio | 1.58 |
| P/FCF Ratio | 15.40 |
| P/OCF Ratio | 11.48 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 24.97, with an EV/FCF ratio of 16.07.
| EV / Earnings | 47.06 |
| EV / Sales | 2.97 |
| EV / EBITDA | 24.97 |
| EV / EBIT | 78.49 |
| EV / FCF | 16.07 |
Financial Position
The company has a current ratio of 1.48, with a Debt / Equity ratio of 0.17.
| Current Ratio | 1.48 |
| Quick Ratio | 1.02 |
| Debt / Equity | 0.17 |
| Debt / EBITDA | 2.09 |
| Debt / FCF | 1.67 |
| Interest Coverage | 25.68 |
Financial Efficiency
Return on equity (ROE) is 3.36% and return on invested capital (ROIC) is 3.45%.
| Return on Equity (ROE) | 3.36% |
| Return on Assets (ROA) | 1.74% |
| Return on Invested Capital (ROIC) | 3.45% |
| Return on Capital Employed (ROCE) | 3.50% |
| Weighted Average Cost of Capital (WACC) | 6.32% |
| Revenue Per Employee | 344.42M |
| Profits Per Employee | 21.75M |
| Employee Count | 718 |
| Asset Turnover | 0.41 |
| Inventory Turnover | 1.95 |
Taxes
| Income Tax | -9.08B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -34.25% in the last 52 weeks. The beta is 0.49, so Medy-Tox's price volatility has been lower than the market average.
| Beta (5Y) | 0.49 |
| 52-Week Price Change | -34.25% |
| 50-Day Moving Average | 112,302.00 |
| 200-Day Moving Average | 124,316.00 |
| Relative Strength Index (RSI) | 51.58 |
| Average Volume (20 Days) | 34,279 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Medy-Tox had revenue of KRW 247.29 billion and earned 15.62 billion in profits. Earnings per share was 2,371.01.
| Revenue | 247.29B |
| Gross Profit | 142.84B |
| Operating Income | 16.68B |
| Pretax Income | 6.58B |
| Net Income | 15.62B |
| EBITDA | 36.75B |
| EBIT | 16.68B |
| Earnings Per Share (EPS) | 2,371.01 |
Balance Sheet
The company has 48.94 billion in cash and 76.63 billion in debt, giving a net cash position of -27.68 billion or -4,223.35 per share.
| Cash & Cash Equivalents | 48.94B |
| Total Debt | 76.63B |
| Net Cash | -27.68B |
| Net Cash Per Share | -4,223.35 |
| Equity (Book Value) | 454.29B |
| Book Value Per Share | 68,895.44 |
| Working Capital | 50.52B |
Cash Flow
In the last 12 months, operating cash flow was 61.41 billion and capital expenditures -15.66 billion, giving a free cash flow of 45.75 billion.
| Operating Cash Flow | 61.41B |
| Capital Expenditures | -15.66B |
| Depreciation & Amortization | 20.07B |
| Net Borrowing | -5.58B |
| Free Cash Flow | 45.75B |
| FCF Per Share | 6,979.08 |
Margins
Gross margin is 57.76%, with operating and profit margins of 6.74% and 6.71%.
| Gross Margin | 57.76% |
| Operating Margin | 6.74% |
| Pretax Margin | 2.66% |
| Profit Margin | 6.71% |
| EBITDA Margin | 14.86% |
| EBIT Margin | 6.74% |
| FCF Margin | 18.50% |
Dividends & Yields
This stock pays an annual dividend of 1,200.00, which amounts to a dividend yield of 1.11%.
| Dividend Per Share | 1,200.00 |
| Dividend Yield | 1.11% |
| Dividend Growth (YoY) | 9.09% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 53.75% |
| Buyback Yield | 2.03% |
| Shareholder Yield | 3.14% |
| Earnings Yield | 2.22% |
| FCF Yield | 6.49% |
Stock Splits
The last stock split was on December 28, 2022. It was a forward split with a ratio of 1.05.
| Last Split Date | Dec 28, 2022 |
| Split Type | Forward |
| Split Ratio | 1.05 |
Scores
Medy-Tox has an Altman Z-Score of 6.12 and a Piotroski F-Score of 6.
| Altman Z-Score | 6.12 |
| Piotroski F-Score | 6 |